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and non-septic critically ill patients
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Abstract 
Purpose: To analyse the usefulness of the composite index of the tissue inhibitor of metalloproteinases‑2 (TIMP‑2) 
and insulin‑like growth factor‑binding protein 7 (IGFBP7) as urinary biomarkers for the early prediction of AKI in septic 
and non‑septic patients.
Methods: This is a prospective, observational study including patients admitted to ICU from acute care departments 
and hospital length of stay <48 h. The main exclusion criteria were pre‑existing eGFR <30 mL/min/1.73 m2 and hospi‑
talisation 2 months prior to current admission. The [TIMP‑2]·[IGFBP7] index was analysed twice, within the first 12 h of 
ICU admission.
Results: The sample included 98 patients. AKI incidence during ICU stay was 50%. Sepsis was diagnosed in 40.8%. 
Baseline renal variables were comparable between subgroups except for a higher baseline eGFR in non‑septic 
patients. Patients were stratified based on the presence of AKI and their highest level of [TIMP‑2]·[IGFBP7] within the 
first 12 h of stay. [TIMP‑2]·[IGFBP7] index values were dependent on the incidence of AKI but not of sepsis. [TIMP‑
2]·[IGFBP7] values were significantly related to AKI severity according to AKIN criteria (p < 0.0001). The AUROC curve to 
predict AKI of the worst [TIMP‑2]·[IGFBP7] index value was 0.798 (sensitivity 73.5%, specificity 71.4%, p < 0.0001). Index 
values below 0.8 ruled out any need for renal replacement (NPV 100%), whereas an index >0.8 predicted a rate of AKI 
of 71% and AKIN ≥ 2 of 62.9%.
Conclusions: In our study, urinary [TIMP‑2]·[IGFBP7] was an early predictor of AKI in ICU patients regardless of sepsis. 
Besides, index values <0.8(ng/mL)2/1000 ruled out the need for renal replacement.
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Background
 Acute kidney injury (AKI) is a frequent complication in 
ICU patients [1]. AKI definitions based on serum cre-
atinine (sCr) have shown a large variation in AKI inci-
dence and associated outcomes [2]. However, it has been 
observed that AKI requiring renal replacement therapy 
(RRT) is an independent factor of poor outcome [3, 4], 
with an associated mortality rate of 50–60% [2, 3].
Sepsis is a relevant contributing factor to AKI develop-
ment. AKI is present in >30% of those with sepsis [5, 6] 
and in >50% of those with septic shock [7, 8]. Pathogens 
producing sepsis and their toxins affect the whole body 
as well as specific organs. Damaging molecules can reach 
the proximal renal tubular cells in high concentrations 
and may trigger kidney injury followed by inflammation 
and oxidative stress and, finally, cell damage [9].
Diagnosis of AKI has changed in the last decade with 
the advent of RIFLE [10], AKIN [11] and KDIGO [12] 
classifications. These tools are based on sCr and diuresis. 
However, sCr is a late and non-specific AKI biomarker 
[13, 14]. Biomarkers that can rapidly and specifically 
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recognise AKI are therefore needed. A few recent stud-
ies have shown that tissue inhibitor of metalloprotein-
ases-2 (TIMP-2) and insulin-like growth factor-binding 
protein 7 (IGFBP7) are specific biomarkers of structural 
renal damage in critically ill patients [15, 16]. Renal 
tubular cells enter in  G1 cell arrest to block the effects 
of molecules contributing to cell-cycle promotion, such 
as cyclins. This mechanism prevents the extension of 
cell damage. TIMP-2 and IGFBP7 are protective mol-
ecules involved in  G1 cell-cycle arrest that moderate 
apoptotic, angiogenic [17], inflammatory [18, 19] and 
ischaemic processes [20]. Since renal cell arrest usually 
occurs 24–48 h before sCr rises due to a significant fall 
in the glomerular filtration rate, TIMP-2 and IGFBP7 are 
thought to be earlier AKI biomarkers than sCr.
TIMP-2 and IGFBP7 are detectable in urine. Previous 
studies in unselected ICU populations have shown that 
when analysed together as the index [TIMP-2]·[IGFBP7], 
they perform better than sCr, urine and plasma NGAL, 
plasma cystatin-C and KIM-1 for early detection of AKI 
and improved risk stratification for renal and general 
outcomes [15, 16]. The aim of this study was to assess 
whether values of the TIMP-2 and IGFBP7 index were 
early predictors of AKI in a selected ICU population 
free of the most frequent AKI risk factors. To date, the 
influence of sepsis on TIMP-2 and IGFBP7 expression in 
critically ill patients is not well defined. As a secondary 
objective, we thus also evaluated the potential usefulness 
of [TIMP-2]·[IGFBP7] index in septic ICU patients.
Methods
The study protocol was approved by the institutional 
review board at each participating centre. We obtained 
informed consent from patients or their guardians. The 
study prospectively included patients over 18 years of age 
with an expected ICU stay of at least 48 h. We included 
patients admitted to ICU either from the emergency 
department or after undergoing acute surgery. Exclusion 
criteria were pregnancy, established anuric AKI, pre-
existing chronic kidney disease (CKD) with estimated 
glomerular filtration rate (eGFR) <30  mL/min/1.73  m2 
and current hospital length of stay >48 h. Medical man-
agement was left to the discretion of the attending physi-
cians. All healthcare providers involved were blinded to 
the biomarkers results.
Sampling and measurement of the [TIMP‑2]·[IGFBP7] 
index
Urine samples for biomarker analysis were collected 
twice: at ICU admission and up to 12 h later simultane-
ously with the morning blood work. Urine samples were 
centrifuged, and supernatants were frozen at ≤−70  °C 
and stored until analysed. Before analysis in a central 
laboratory at Hospital de la Santa Creu i Sant Pau, ali-
quots were thawed at room temperature and centri-
fuged at 3000  rpm for 15  min. A previous study in the 
central laboratory showed there were no significant 
differences in the [TIMP-2]·[IGFBP7] index between 
fresh and frozen urine samples (data not shown). The 
[TIMP-2]·[IGFBP7] index was measured by a sandwich 
fluorescent quantitative immunoassay adapted to a port-
able device  (Nephrocheck®, Astute Medical). All samples 
were analysed in the same batch to avoid between-batch 
variability. The portable device provides a [TIMP-
2]·[IGFBP7] index in ((ng/mL)2/1000) units. According 
to the manufacturer, an index ≤0.3 suggests a low risk of 
AKI, values between 0.3 and 2.0 suggest a high risk, and 
values >2.0 suggest a very high risk [15].
Data collection
Clinical data included patient demographics and comor-
bidities. The APACHE II score, the SAPS II and the 
SOFA score were recorded at ICU admission. Patients 
were classified following the AKIN classification [11], 
which includes changes in sCr and urine output. Base-
line sCr was taken from patients’ pre-admission records 
whenever possible and used to estimate eGFR before ICU 
admission using the Cockcroft–Gault formula. When 
baseline sCr was not available, AKI was defined only with 
AKIN urine output criterion. Sepsis and septic shock 
were defined according to standard criteria [1, 21].
Statistical analysis
IBM®  SPSS® version 21 (IBM corp., Armonk, NY) was 
used. Variables with Gaussian distribution are reported 
as mean ±  standard deviation and were compared with 
the Student’s t test or one-way analysis of variance. Vari-
ables with a non-Gaussian distribution are reported as 
median and interquartile range (IQR) and were com-
pared with Mann–Whitney’s U or Kruskal–Wallis tests. 
Categorical data are reported as percentage and were 
compared using Chi-square test or Fisher exact test.
The primary outcome of the study was AKI prediction 
with the [TIMP-2]·[IGFBP7] index. For statistical analy-
ses, we used the highest value observed during the first 
12 h of ICU admission as the worst index. Reporting of 
results followed the Standards for Reporting Diagnos-
tic Accuracy Studies (STARD) statement. As [TIMP-
2]·[IGFBP7] index provides a quantitative result that it 
is interpreted with two cut-offs, analysis was performed 
to establish the diagnostic accuracy of the test in com-
parison with the reference standard, which is the AKIN 
definition of AKI. Diagnostic values, positive predictive 
values (PPV) and negative predictive values (NPV) were 
assessed a priori for AKI statistically relevant variables by 
the area under the receiver operator characteristic curve 
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(AUROC) and by the odds ratio (OR). Results were pre-
sented with a 95% confidence interval and probability 
(p). For selected thresholds of [TIMP-2]·[IGFBP7], sensi-
tivities, specificities, PPV and NPV were reported for the 
worst [TIMP-2]·[IGFBP7] value within the first 12  h in 
the ICU. The ROC analysis was used to calculate the best 
[TIMP-2]·[IGFBP7] cut-off point for AKI and AKIN ≥ 2 
prediction. A p < 0.05 was considered significant.
Results
We recruited 100 consecutive patients fulfilling the 
admission criteria in the ICU of two university hospi-
tals, from June 2011 to April 2013. Two patients were 
excluded from the study because one of their samples 
was missing (Fig.  1). Table  1 includes the main charac-
teristics and outcomes of the overall study population as 
well as in subgroups depending on the occurrence of AKI 
and sepsis at admission. Further epidemiological data are 
included in Additional file 1: Table S1.  
At admission, 44 patients presented some grade of 
AKI, more frequently observed in septic patients; 19 
fulfilled criteria for AKIN 1, 20 AKIN 2 and 5 AKIN 
3. Throughout ICU admission AKI affected 49 of 98 
patients. The incidence of AKIN ≥ 2 increased from 25.5 
to 31.6% in those patients who presented AKI. Five of 98 
patients required RRT within the first 48 h of admission. 
40.8% had sepsis at ICU admission.
When comparing subgroups depending on the occur-
rence of AKI and sepsis in ICU (Table 1; Additional file 1: 
Table S1), those patients in AKI or sepsis categories were 
older and had a higher incidence of shock and higher 
severity scores. Although the incidence of shock in both 
subgroups was higher, there was no statistical difference 
in the incidence of septic shock between the non-AKI 
and AKI subgroups. Septic patients also showed a lower 
baseline eGFR. However, baseline sCr and the remaining 
patients’ characteristics for both subgroups did not differ.
Overall mortality was 10.2% in ICU, and 12.2 and 
13.3%, respectively, at 28 and 90 days (Table 1; Additional 
file 1: Table S1).
Composite index of [TIMP‑2]·[IGFBP7]
[TIMP-2]·[IGFBP7] index values were significantly 
higher in patients with AKI (1.03, IQR 0.38–3.29) than 
Fig. 1 Diagram of [TIMP‑2]·[IGFBP7] index to predict AKI, study enrolment and inclusion
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in those without AKI (0.24, IQR 0.11–0.48) (p  <  0.001) 
(Table  1). These differences were unrelated to the pres-
ence of sepsis (Table 2). Patients who developed AKI pre-
sented higher median index values (1.05, IQR 0.41–2.31 
for patients without sepsis; 0.98, IQR 0.36–3.94 for sep-
tic patients) than those without AKI (0.21 IQR 0.10–0.40 
in non-septic patients and 0.32 IQR 0.15–0.63 for those 
with sepsis) with p  <  0.001 between subgroups with 
and without AKI (no statistical differences were found 
between septic and non-septic status).
The index values were significantly related to AKI pres-
ence and severity according to AKIN criteria (Fig. 2). In 
contrast, index values did not appear to be influenced by 
sepsis, either in AKI or non-AKI patients (Table 2).
[TIMP-2]·[IGFBP7] values increased in 44% of patients 
within 12  h of ICU admission; index values decreased 
in all other patients. Overall, a repeated determina-
tion of [TIMP-2]·[IGFBP7] did not show any differences 
between non-AKI/AKI and non-septic/septic subgroups 
(Additional file 2: Figure S1).
We divided the patients into 3 subgroups depending on 
the cut-offs proposed in previous studies [15] (Table 3). 
Although baseline sCr showed no statistically signifi-
cant difference between subgroups, baseline eGFR sig-
nificantly declined at index values >2.0. AKI occurrence 
and AKIN ≥  2 during ICU stay were significantly more 
frequent in the groups with index >0.31. However, the 
need for RRT did not differ according to the index val-
ues. There were also differences between subgroups in 
the incidence of shock, SAPS II score and ICU length of 
stay. Patients with high-risk values also had longer ICU 
length of stay but not hospital length of stay, both with 
Table 1 Main characteristics of the study population in subgroups of AKI/non-AKI and septic/non-septic patients
Values expressed as either % per column, mean ± standard deviation or median and interquartile range. p value of statistical significance
NS no statistical significance, AKI acute kidney injury, AKIN acute kidney injury network definition, APACHE II acute physiology and chronic health evaluation II, ICU 
intensive care unit, LOS length of stay, SAPS II Simplified Acute Physiology Score II, SOFA sequential organ failure assessment score
Total Non‑AKI AKI p value Non‑septic Septic p value
n 98 49 49 – 58 40 –
Men 65 (66.3%) 30 (61.2%) 35 (71.4%) NS 38 (65.5%) 27 (67.5%) NS
Age (years) 55 ± 17.3 50.4 ± 17.9 59.9 ± 15.5 0.006 50.9 ± 16.6 61.2 ± 16.8 0.003
Renal characteristics
 Baseline eGFR (mL/min) n = 86 110.6 ± 53.7 120.5 ± 60.5 100.7 ± 44.6 NS 121.9 ± 58.9 94.8 ± 41.2 0.020
 Baseline creatinine (μmol/L) n = 86 79 ± 31.5 80.5 ± 32.3 78.1 ± 31.1 NS 79.6 ± 28.9 78.9 ± 35.1 NS
 Creatinine upon ICU admission 94.1 ± 42.2 74.6 ± 30.2 113.1 ± 43.9 <0.001 85.0 ± 36.8 106.9 ± 46.5 0.015
 AKI at admission 44 (44.9%) – 44 (89.8%) – 20 (34.5%) 24 (60%) 0.013
 AKIN ≥ 2 upon ICU admission 25 (25.5%) – 25 (51%) – 9 (15.5%) 16 (40%) 0.009
 Renal replacement <48 h 5 (5.1%) 0 (0%) 5 (10.2%) 0.056 4 (6.9%) 1 (2.5%) NS
 Worst value [TIMP‑2]·[IGFBP7] ((ng/
mL)2/1000)
0.41 (0.20–1.36) 0.24 (0.11–0.48) 1.03 (0.38–3.29) <0.001 0.36 (0.14–1.08) 0.56 (0.26–2.94) NS
ICU epidemiological data
 Shock 35 (35.7%) 11 (22.5%) 24 (50%) 0.011 10 (17.2%) 25 (62.5%) <0.001
 Septic shock 19 (19.4%) 6 (12.3%) 13 (26.5%) NS – 19 (47.5%) –
 Mechanical ventilation 79 (80.6%) 39 (79.6%) 40 (81.6%) NS 44 (75.9%) 35 (87.5%) NS
 SAPS II 37.4 ± 18.3 30.9 ± 14.9 43.9 ± 19.2 <0.001 30.9 ± 15.6 46.8 ± 18.1 <0.001
 APACHE II 15.7 ± 8.2 13.5 ± 7.7 17.9 ± 8.2 0.007 14.2 ± 8.5 17.9 ± 7.3 0.024
 SOFA at ICU admission 7.5 ± 3.7 6.1 ± 3.2 8.9 ± 3.7 <0.001 6.7 ± 3.7 8.7 ± 3.4 0.009
 ICU LOS (days) 11.1 ± 14.6 10.0 ± 10.6 12.3 ± 18.8 NS 9.3 ± 11.0 13.9 ± 18.5 NS
 Hospital LOS (days) 23.6 ± 25.0 23.4 ± 23.3 23.8 ± 27.0 NS 21.4 ± 21.3 26.9 ± 29.6 NS
 ICU mortality 10 (10.2%) 4 (8.2%) 6 (12.3%) NS 6 (10.3%) 4 (10%) NS
Table 2 Worst [TIMP-2]·[IGFBP7] distribution within  12  h 
of ICU admission depending on AKI and sepsis
(AKI + vs. AKI −) and (Sepsis + vs. Sepsis −) represent the presence or absence 
of either AKI during hospital stay or sepsis upon admission, respectively. Values 
show median and percentiles 25–75. p represents the statistical intra-group 
differences. [TIMP-2]·[IGFBP7] values given in ((ng/mL)2/1000)
AKI acute kidney injury, NS no statistical differences
AKI − p value AKI +
Sepsis − 0.21 (0.10–0.40) 
(n = 35)








Sepsis + 0.32 (0.15–0.63) 
(n = 14)
⇐ p = 0.009 ⇒ 0.98 (0.36–3.94) 
(n = 26)
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wide standard deviation. According to the manufactur-
er’s [TIMP-2]·[IGFBP7] stratification, both subgroups of 
patients with high and very high-risk values needed RRT. 
There were no differences between subgroups regarding 
ICU mortality or mortality at 28 and 90 days.
We assessed the best predictive cut-off of [TIMP-
2]·[IGFBP7] index to predict AKI and AKIN ≥ 2.0 in our 
population. Table 4 details the sensitivity and specificity 
of [TIMP-2]·[IGFBP7] test with increasing indexes, as 
well as the overall accuracy of the test to predict AKI and 
AKIN ≥ 2. The AUROC curve of the worst value [TIMP-
2]·[IGFBP7] within the first 12  h of ICU admission for 
AKI prediction was 0.798 (0.709–0.886, p < 0.0001)) for 
an index value of 0.40, with sensitivity of 73.5% (95% CI 
69.7–77.5%) and specificity of 71.4% (95% CI 67.4–75.4%) 
(Table 4; Fig. 3). To predict AKIN ≥ 2, the AUROC was 
0.805 (0.700–0.909, p  <  0.0001) with an index value of 
0.80, sensitivity of 72.0% (95% CI 68.1–75.9%) and speci-
ficity of 78.1% (95% CI 74.6–81.8%).
Patients with index values ≥0.80 (ng/mL)2/1000 were 
older (Table 3). Our threshold did not reveal differences 
in baseline sCr, baseline eGFR, ICU or hospital length 
of stay between subgroups. The incidence of shock was 
higher in patients with index values ≥0.8, although this 
difference was only marginally significant (p  =  0.053). 
However, all patients requiring RRT showed an index 
value ≥0.8. Thus, compared with the values previously 
reported in other studies, the observed cut-offs identified 
25 additional patients that would not require RRT.
We also evaluated PPV and NPV for both sets of cut-
offs (data not shown). However, both sets were equally 
able to differentiate patients with AKI and AKIN  ≥  2. 
Although the low incidence of RRT per se increases the 
NPV, our own specific cut-offs better classified those 
Fig. 2 Boxplot comparing the worst [TIMP‑2]·[IGFBP7] index and sCr upon admittance with the worst AKIN. Boxplots indicate the median, 25th and 
75th percentiles. Whiskers indicate the 5th and 95th percentiles. Statistical significance (p) comparing each biomarker index with AKIN and RIFLE 
categories. p was determined by Kruskal–Wallis test, not correlation. We found statistical differences in the worst [TIMP‑2]·[IGFBP7] index concentra‑
tions when comparing the subgroup without AKI with any degree of AKI defined by AKIN. Between non‑AKI and AKIN 1, p was 0.014 and p < 0.001 
when comparing with AKIN 2 and AKIN 3. In between AKIN 1 and AKIN 3, p = 0.004, whereas in between AKIN 2 and AKIN 3 p = 0.039. When 
comparing sCr levels with AKIN, we found differences between the subgroup without AKI with AKIN 1 (p = 0.008), AKIN 2 and 3 (for both p < 0.001). 
In between AKIN 1 and 3, p was 0.048 and p = 0.033 in AKIN 2 versus AKIN 3
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patients who finally underwent RRT (p = 0.007), with a 
NPV of 100% (95% CI 96.4–100%) for a cut-off >0.8 ((ng/
mL)2/1000) versus 96.2% (95% CI 92–100%) for a cut-
off >2  ((ng/mL)2/1000). Values above 2  ((ng/mL)2/1000) 
could only rule out the need of RRT in 40% of cases (95% 
CI 0–83%).
Taking into account the characteristics of our popu-
lation (Tables  1, 3), we conducted stepwise logistic 
Table 3 Population characteristics depending on different cut-offs of [TIMP-2]·[IGFBP7] index for AKI diagnose
Values expressed as either % of cases per row or mean ± standard deviation. p value of statistical significance
In our database, five patients had a much longer length of stay (51, 53, 60, 68 and 97 days) than the overall group (≤30 days). Four of these five patients presented 
index values 0.31–2 ((ng/mL)2/1000), which may explain this finding
NS no statistical significance, AKI acute kidney injury, AKIN acute kidney injury network definition, APACHE II acute physiology and chronic health evaluation II, ICU 
intensive care unit, LOS length of stay, SAPS II Simplified Acute Physiology Score II, SOFA sequential organ failure assessment score
Worst [TIMP‑2]·[IGFBP7] index within the first 12 h in ((ng/mL)2/1000)
≤0.3 0.31–2 >2 p value ≤0.4 0.41–0.8 >0.8 p value
n 38 40 20 – 47 16 35 –
Men (n = 65) 21 (55.3%) 30 (75%) 14 (70%) NS 29 (61.7%) 12 (75%) 24 (68.6%) NS




84 ± 31.9 72 ± 28.5 85 ± 34.9 NS 83 ± 30.1 66 ± 33.3 80 ± 32 NS
 Baseline eGFR 
(mL/min) 
n = 86
117 ± 60.1 
(n = 31)
123 ± 48.1 
(n = 35)
79 ± 40.9 
(n = 20)
0.008 112 ± 55.4 
(n = 39)
128 ± 54.1 
(n = 12)
103 ± 52.7 
(n = 35)
NS
 AKI while in ICU 
(n = 49)
9 (23.7%) 22 (55%) 18 (90%) <0.001 13 (27.7%) 8 (50%) 28 (80%) <0.001
 AKIN ≥ 2 
while in ICU 
(n = 31)
4 (10.5%) 13 (32.5%) 14 (70%) <0.001 6 (12.8%) 3 (18.8%) 22 (62.9%) <0.001
 RRT <48 h 
(n = 5)
0 (0%) 3 (7.5%) 2 (10%) NS 0 (0%) 0 (0%) 5 (14.3%) 0.007
ICU epidemiological data
 Sepsis at admis‑
sion (n = 40)
11 (29%) 18 (45%) 11 (55%) NS 16 (34%) 8 (50%) 16 (45.7%) NS




32 (84.2%) 32 (80%) 15 (75%) NS 39 (83%) 13 (81.3%) 27 (77.1%) NS
 SAPS II 35 ± 15.4 34 ± 17.4 49 ± 21.1 0.004 35 ± 16.2 28 ± 11.9 44 ± 21.1 0.006
 APACHE II 16 ± 8.7 15 ± 7.5 17 ± 8.8 NS 15 ± 8.2 13 ± 6.0 18 ± 8.8 NS
 SOFA at ICU 
admission
7 ± 3.5 7 ± 3.9 8 ± 3.8 NS 7 ± 3.8 7 ± 3.7 8 ± 3.5 NS
 ICU LOS 8.6 ± 9.1 15.6 ± 20.1 7.0 ± 5.3 0.036 8.8 ± 8.7 12.6 ± 15.8 13.6 ± 19.6 NS
 Hospital LOS 24.6 ± 25.9 24.9 ± 28.9 19.2 ± 12.5 NS 23.6 ± 24.9 20.8 ± 16.1 24.9 ± 28.7 NS
 ICU mortality 
(n = 10)
4 (10.5%) 4 (10%) 2 (10%) NS 4 (8.5%) 1 (6.3%) 5 (14.3%) NS
Table 4 Diagnostic and overall accuracy of [TIMP-2]·[IGFBP7] for AKI compared with gold standard AKIN classification
AUC area under curve of ROC analysis; CI confidence interval; Se sensitivity; Sp specificity
[TIMP‑2]·[IGFBP7] cut‑off value ((ng/mL)2/1000) Se % 95% CI Sp % 95% CI AUC 95% CI
0.3—to predict AKI 81.6 78.2–85.0 59.2 54.9–63.5 0.80 0.71–0.89
0.4—to predict AKI 73.5 69.7–77.5 71.4 67.4–75.4
0.8—to predict AKIN ≥ 2 72.0 68.1–75.9 78.1 74.6–81.8 0.81 0.70–0.91
2.0—to predict AKIN ≥ 2 48.0 43.6–52.4 90.4 87.8–93.0
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regression analysis using as covariates age, sepsis, shock, 
previous hepatopathy, secondary ARDS, SAPS II, SOFA 
at admission and the worst value [TIMP-2]·[IGFBP7] for 
AKI and AKIN ≥ 2 prediction. In our equation, [TIMP-
2]·[IGFBP7] index showed an OR of 3.15 (95% IC 1.60–
6.17, p  =  0.001) for AKI prediction and 1.85 (95% IC 
1.33–2.57, p = 0.001) for AKIN ≥ 2 prediction.
Discussion
Our results showed that the [TIMP-2]·[IGFBP7] index is 
a useful predictor of AKI in the first 12 h of ICU admis-
sion in both septic and non-septic critically ill patients 
otherwise free of common AKI risk factors. Our AUROC 
curves of [TIMP-2]·[IGFBP7] for prediction of both AKI 
and AKIN ≥ 2 (0.798 and 0.805, respectively) agreed with 
the results already described in the literature [15, 22–25]. 
A recently published subgroup analysis of septic patients 
in sapphire and topaz studies shows similar results [26]. 
In our study, patients with high index values showed a 
3.15- and a 1.85-fold risk to present AKI and AKIN ≥ 2, 
respectively. The most relevant finding in our study is 
that a cut-off [TIMP-2]·[IGFBP7] of 0.8 ((ng/mL)2/1000) 
showed a NPV 100% for RRT requirement. Thus, beyond 
their AKI prognostic capacity, these biomarkers also 
ruled out the need for RRT below this threshold over the 
first 12 h of ICU admission.
Sepsis is a common feature in ICU patients [1]. In our 
study, 40.8% of patients were septic at ICU admission 
and had a higher incidence of AKIN ≥  2. Gómez’s uni-
fied theory of sepsis-induced AKI may explain why some 
critically ill patients can present AKI in hyperdynamic 
and/or non-hypotensive status [27]. AKI and sepsis are 
reciprocal risk factors. Sepsis triggers inflammation and 
oxidative stress, and promotes microvascular dysfunc-
tion, which can lead to AKI. On the other hand, AKI 
impairs monocyte cytokine production and elevates 
plasma cytokine levels [28], acting as a sepsis risk factor. 
The fact that [TIMP-2]·[IGFBP7] are independently asso-
ciated with AKI in sepsis is a relevant advantage of these 
biomarkers compared with more widely described NGAL 
or cystatin-C [29–31].
Another important finding regards the timing to ana-
lyse [TIMP-2]·[IGFBP7]. Repeated determinations of 
any biomarker in a short period of time may reduce their 
intrinsic variability and increase their diagnostic or prog-
nostic power. We performed two [TIMP-2]·[IGFBP7] 
determinations (admission and up to 12  h later) for 
each patient. In a post-operative cardiac surgery setting, 
Meersch [23, 32] showed that [TIMP-2]·[IGFBP7] rose as 
fast as 4 h after surgery (AUROC 0.84, Se 0.92 Sp 0.81) 
for the highest concentration of [TIMP-2]·[IGFBP7] 
within the first 24  h. However, in our study, repeated 
determinations did not improve prediction. This is rel-
evant because a single analysis is easier to implement and 
decreases costs. The manufacturer recommends repeat 
testing of patients with an inconclusive result. We would 
only suggest considering repeating the test in those cases 
in which clinically their result is difficult to interpret.
Our study tested these biomarkers in a selected ICU 
population free of common AKI risk factors [33]. Most 
Fig. 3 ROC curve for the worst [TIMP‑2]·[IGFBP7] index to predict AKI and AKIN ≥ 2. ROC curve and area under the curve (AUC) for the worst [TIMP‑
2]·[IGFBP7] index concentration within the first 12 h of ICU admission to predict AKI (left) and AKIN ≥ 2 (right)
Page 8 of 10Cuartero et al. Ann. Intensive Care  (2017) 7:92 
studies analysing the role of classical or emerging bio-
markers in ICU subjects have been done in unselected 
populations. Accordingly, the number of patients pre-
senting different degrees of renal dysfunction is variable, 
but usually high. AKI is a common complication of many 
non-renal hospitalisations [34, 35]; it has been estimated 
that the incidence of hospital-acquired renal insufficiency 
is about 7% [36]. Ideally, to describe the characteristics of 
a new AKI biomarker this incidence should be studied in 
subjects with a normal baseline renal function. Although 
our patients may not fully represent an average ICU pop-
ulation in view of our selective inclusion and exclusion 
criteria, our approach decreases the confounding effect 
of intra-hospital risk factors to develop AKI, such as 
exposure to nephrotoxics, hypotension and nosocomial 
sepsis.
Patients with AKI and/or sepsis showed higher severity 
scores, and ICU and hospital length of stay, although the 
latter did not reach statistical difference. Mortality rates 
remained very low. Thus, we did not find significant dif-
ferences. This could be partially explained because of our 
study exclusion criteria. We excluded patients with estab-
lished anuric AKI at admission, who had the highest risk 
for poor outcome related to AKI [2, 3], and patients with 
an expected ICU length of stay <2 days because of their 
severe condition. Besides, we did not recruit those sub-
jects who had already been hospitalised. In a subanalysis 
of the PICARD study [37], which analysed the relation-
ship between AKI and sepsis, septic patients either before 
or after AKI onset presented higher mortality rates than 
non-septic patients (48, 44 and 21%, respectively).
We also clinically assessed the cut-off values described 
in the literature. The sapphire and opal studies [15, 16] 
reported the same cut-off values for the risk of AKI 
development. In our cohort, the best cut-off index values 
were 0.4 and 0.8 ((ng/mL)2/1000) to differentiate no AKI 
risk, high risk and very high risk (Table 4). The lower cut-
off was very close to the 0.3 previously reported, and it 
is in keeping with the value cited in the FDA report [38]. 
Thus, the lower threshold may be helpful to consider 
before the indication of procedures involving nephrotox-
ics or to avoid starting RRT in oliguric patients. We also 
found a consistent NPV above 70% to exclude any degree 
of AKI. When using our own threshold for very high 
risk of AKI [0.8  ((ng/mL)2/1000)], we did differentiate 
all patients who finally underwent RRT (p = 0.007). The 
controversy arises in the 0.41–0.8 ((ng/mL)2/1000) range; 
although this subgroup of patients might benefit from a 
second sampling, this is not supported by our results.
The main limitations in our study are the small sample 
size and the enrolment in only two centres. Although the 
overall findings are consistent with recent studies, our 
thresholds do need further validation. The main strength 
of the study is the clinical design. The restricted inclusion 
criteria reduced the size of our cohort and the statisti-
cal power, which may also explain the low mortality rate. 
However, we obtained most baseline sCr and we ensured 
that patients who developed AKI did not have previous 
significant CKD. Unlike most observational studies, our 
proof of model selection of patients also ruled out the 
added effect of intra-hospital risk factors for AKI.
Conclusions
Unlike other renal biomarkers, [TIMP-2]·[IGFBP7] 
predict AKI in both septic and non-septic critically 
ill patients. These biomarkers are especially useful to 
promptly differentiate patients without AKI from those 
with a very high risk of developing AKI. Below the cut-
off value of 0.8 ((ng/mL)2/1000), the [TIMP-2]·[IGFBP7] 
index was able to exclude those patients who needed 
RRT in our study population.
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